April 12, 2026

Can you commercialise science you have already defunded

RDECOM's Advanced Chemistry Laboratory is on the forefront of science

New Zealand’s science overhaul has a correct diagnosis and a dangerous prescription. The system has been poor at turning publicly funded research into exportable companies. The government’s response, detailed across 21 delivered actions since February 2025, is to redirect money toward commercialisation and advanced technology. The problem is that the money being redirected is not new money. It is being stripped from the upstream research that commercialisation depends on.

The Science System Advisory Group’s own final report described New Zealand’s science system as “particularly fragile” and warned that chronic underinvestment had driven the country’s sluggish productivity. The reforms respond to that warning by rearranging the budget rather than growing it.

The numbers behind the shuffle

The headline commitments look impressive in isolation: $231 million for the New Zealand Institute for Advanced Technology, $71 million in advanced technology platforms, and $70 million over seven years for AI research.

But the April 2026 funding reallocation reveals the trade-offs. The Prime Minister’s Science, Innovation, and Technology Advisory Council recommended pulling $56 million over three years from primary industries and bioeconomy, a 22% cut, alongside $18 million from environmental sustainability and $37 million from human and social health. The combined total delivers an 88% increase, or $111 million over three years, to advanced technology.

Meanwhile, the Marsden Fund, historically the gold standard for curiosity-driven research, now requires 50% of grants to demonstrate economic benefit. Social sciences and humanities have been removed entirely. Eighty Rutherford Discovery Fellows signed an open letter condemning the changes.

You cannot commercialise what you have defunded

Dr James Hutchinson, CEO of KiwiNet, the organisation that exists to translate research into commercial outcomes, put it plainly: “game-changing innovation does not come from translation alone”. He warned the government not to “treat this as a zero-sum exercise at current funding levels”.

Professor Rod McNaughton at the University of Auckland reinforced the point, noting that “many of today’s most transformative technologies, mRNA vaccines, AI, and quantum computing, emerged from long-term, curiosity-driven research”. The critics’ favourite irony is apt: Ernest Rutherford’s work on atomic structure would likely fail the new “real impact” requirement.

The funding gap makes all of this harder. Stats NZ’s 2023 R&D survey shows business R&D reached $3.7 billion, up 17%, but R&D as a proportion of GDP sat at just 0.95%, less than half the government’s own 2% target. Minister Collins regularly cites Israel as a model. Professor Frédérique Vanholsbeeck notes the comparison cuts both ways: “Israel is investing about 5.9% of GDP in R&D. New Zealand is barely at 1.5%”.

More troubling, the number of businesses performing R&D fell 2.3% to 2,286 while average spend per firm rose 20%. R&D is concentrating among fewer, larger players rather than broadening across the economy.

Cutting farm science in a farming economy

The 22% cut to primary industries research deserves particular scrutiny. The government’s logic, that mature sectors can attract private funding, is not unreasonable. But agricultural R&D has a significant public-good component that private firms will not fund because they cannot capture the returns: biosecurity, climate adaptation, environmental stewardship.

Dr Lucy Stewart of the NZ Association of Scientists was direct: “we are a country whose economy depends very heavily on the environment. Decreasing funding from all other areas will inevitably lead to further loss of capability”. Dr Troy Baisden called the primary industries cut “catastrophic” and warned it would hit hardest in agricultural regions that will see no near-term benefit from NZIAT or advanced tech platforms.

One board, one minister, one point of failure

The structural changes consolidate the Endeavour, Marsden, and Strategic Science Investment funds under a single body, Research Funding New Zealand, governed by an eight-member board with direct ministerial oversight. Dame Jane Harding, president of the Royal Society Te Apārangi, warned that “future funding decisions could be influenced, or perceived to be influenced, by factors beyond the excellence of the research”.

Professor Richard Easther captured the asymmetric risk: “if it brings Marsden’s rigour to MBIE projects it will succeed, but if it goes the other way it will be a disaster”.

The fiscal wall that makes this permanent

Treasury’s 2025 Investment Statement forecasts Crown net worth falling 10% to $172 billion by 2029. The zero-sum nature of this debate is not a temporary constraint. It is the structural condition under which these reforms will operate for years. As researcher Priscilla Wehi put it: “The trouble with the Government’s idea for a simple, more efficient science fund is that it’s trying to be a Ferrari on tin can funding”.

Business owners who want a more commercial science system should want these reforms to succeed. But the companies most likely to benefit from a healthy deep-tech pipeline in 2035 are being asked to back a strategy that may hollow out the very research base they will need. Professor Easther’s orchard metaphor lands hardest: “while every government has asked what fruits can be harvested from science they have shown little interest in the health of the actual trees”. Demanding fruit from trees you refuse to water is not a growth strategy. It is liquidation by another name.

Sources

Subscribe for weekly news

Subscribe For Weekly News

* indicates required